Filing Flows › Nektar Therapeutics (NKTR) › Q4 2024
Nektar Therapeutics (NKTR) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 14, 2025
Nektar Therapeutics (NKTR) reported revenue of $29.2M for the fourth quarter 2024 (Q4 2024), +22% from a year earlier and +21% from the quarter before. Operating margin was 49.2%, net earnings $7.3M (24.9% of revenue).
Nektar Therapeutics, Q4 2024: revenue $29.2M (+22% year over year), operating margin 49.2%, net earnings $7.3M, operating cash flow −$46.2M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $29.2M | +21% | +22% |
| Operating profit | $14.3M | — | — |
| Net earnings | $7.3M | — | — |
| Operating cash flow | −$46.2M | — | — |
What changed
Revenue was $29.2M in Q4 2024, up 22% year over year and up 21% from the previous quarter. Non Cash Royalty Revenue Related to Sale of Future Royalties was the largest line at 56% of revenue.
Operating profit was $14.3M, a 49.2% margin (up 189.5 points year over year). Total costs fell 74% while revenue rose 22%. Net earnings were $7.3M. The effective tax rate was -3.7%.
Operating cash flow was −$46.2M. Non-cash charges added back $332K of depreciation and amortization and $4.8M of share-based compensation. Working capital and other items used $58.6M. Capital expenditures of $459K exceeded it, leaving free cash flow of −$46.6M.
Questions
What was Nektar Therapeutics' revenue in the fourth quarter 2024?
Nektar Therapeutics (NKTR) reported revenue of $29.2M for the fourth quarter 2024 (Q4 2024), +22% from a year earlier and +21% from the quarter before.
Was Nektar Therapeutics profitable in the fourth quarter 2024?
Operating profit was $14.3M (49.2% of revenue) and net earnings $7.3M.